Insmed price to book ratio INSM

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 26.9×
10-year median: 10.6×
Against its 10-year history: 75th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.1× to 200×
Peer median: 6.1×

Insmed's price to book ratio is 26.9× as of Oct 23, 2026.

That is above its ten-year median of 10.6×, higher than on 75% of days in the last ten years.

Over that time it ranged from 3.1× in Dec 2018 to 200× in Aug 2025.

The median for 10 biotech stocks of a similar size is 6.1×.

Price to book ratio over time

median 10.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.9×	26.9×	48.1×
2025	40.1×	18.5×	200×
2024	25.8×	24.5×	27.9×
2023	30.2×	25.5×	31.9×
2022	50.1×	5.0×	75.3×
2021	6.4×	5.1×	16.7×
2020	9.5×	4.9×	12.9×
2019	7.0×	3.9×	15.7×
2018	3.5×	3.1×	5.8×
2017	5.7×	4.0×	23.4×
2016	3.8×	2.1×	4.3×
2015	3.3×	2.9×	10.1×
2014	3.8×	3.3×	6.0×
2013	4.3×	1.3×	6.0×
2012	1.5×	0.5×	1.8×
2011	0.5×	0.5×	0.7×

Against its peers

Companies in Biotechnology nearest Insmed's size, closest first, today.

Company	Price to book ratio
INSMInsmed	26.9×
INCYIncyte	3.7×
UTHRUnited Therapeutics	3.9×
EXELExelixis	8.7×
NBIXNeurocrine Biosciences	3.9×
HALOHalozyme Therapeutics	99.3×
ALNYAlnylam Pharmaceuticals	22.1×
TECHBIO-TECHNE	5.4×
RGENRepligen	4.7×
ONCBeOne Medicines	8.3×
KRYSKrystal Biotech	6.8×
Peer median	6.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Insmed

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.